© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.